Hashimoto encephalopathy

Julien Rousseau MDCM (

Dr. Rousseau of Université de Montréal has no relevant financial relationships to disclose.

Sarah Lapointe MD (

Dr. Lapointe of the University of Montreal has no relevant financial relationships to disclose.

Francesc Graus MD PhD, editor. (

Dr. Graus, Emeritus Professor, Laboratory Clinical and Experimental Neuroimmunology, Institut D’Investigacions Biomédiques August Pi I Sunyer, Hospital Clinic, Spain, has no relevant financial relationships to disclose.

Originally released May 10, 2018; last updated October 30, 2020; expires October 30, 2023


Hashimoto encephalopathy is a controversial and poorly understood diagnosis classically defined as a steroid-responsive encephalopathy associated with thyroid autoimmunity. The key features are: (1) altered level of consciousness and (2) presence of anti-thyroid peroxidase (anti-TPO) or anti-thyroglobulin (anti-TG) antibodies. It is distinct from alterations in mentation that may occur due to severe hyper- or hypothyroidism, and severe abnormalities in thyroid hormone levels should be excluded when making the diagnosis. Symptoms can vary considerably though commonly include cognitive deficits, behavioral changes, myoclonus, stroke-like episodes, and seizures.

Patients with suspected Hashimoto encephalopathy require careful evaluation for autoimmune and nonautoimmune causes of encephalopathy.

Key points


• Hashimoto encephalopathy is a poorly understood syndrome of reversible cognitive impairment in the setting of antithyroid autoantibodies.


• There are no validated criteria for the diagnosis of the disease but proposed diagnostic criteria include: (1) encephalopathy with seizures, myoclonus, or stroke-like episodes; (2) subclinical or mild overt thyroid disease; (3) normal or nonspecific abnormalities on brain MRI; (4) positive serum anti-TPO or anti-TG antibodies; (5) absence of well-characterized neuronal antibodies in CSF and serum; (6) reasonable exclusion of alternative causes.


• The literature on Hashimoto encephalopathy is highly heterogenous and most reports did not adequately exclude alternative diagnoses, such as other causes of autoimmune encephalitis.


• Antithyroid antibodies are relatively common in the general population and may also be found in patients with other, better-defined types of autoimmune encephalitis.


• The existence of the disease has been seriously questioned in recent years owing to its nonspecific diagnostic criteria and to a lack of distinct biomarkers.


• There is no class 1 evidence for treatment of Hashimoto encephalopathy.

Historical note and terminology

In 1966, Brain and colleagues reported the initial case of Hashimoto encephalopathy, a 40-year-old man with antithyroid antibodies who had multiple stroke-like episodes and periods of profound confusion (Brain et al 1966). He eventually had excellent recovery (although he did not obviously respond to corticosteroids). Though he had thyroid disease, this was well controlled during most of his clinical course. The authors concluded that he may have had an autoimmune disease but doubted that the antithyroid antibodies were directly pathogenic.

In the last decade, alternative names for Hashimoto encephalopathy have been proposed, including steroid-responsive encephalopathy associated with thyroiditis (SREAT) and encephalopathy associated with autoimmune thyroid disease (EAATD).

Hashimoto encephalopathy should not be confused with Hashimoto thyroiditis. Hashimoto thyroiditis was first described in 1912 as a form of thyroid disease with lymphomatous infiltrates (Hiromatsu et al 2013). Unlike Hashimoto encephalopathy, humoral factors such as antibodies to thyroid peroxidase, thyroglobulin, and other antithyroid antibodies are thought to directly contribute to the pathogenesis of Hashimoto thyroiditis, along with cellular immunity, genetic risk, and other factors (Ajjan and Weetman 2015). The diagnosis of Hashimoto thyroiditis is based on the presence of primary hypothyroidism (elevated TSH, low T4), goitrous or atrophic thyroid changes, and can be confirmed by the presence of anti-TPO or anti-TG antibodies.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology